人人干人人摸人人骑-人人干人人澡-人人干天天搞夜夜爽-人人干综合-人人搞人人摸-人人搞人人模

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 午夜无码国产理论在线 | 波尔野吉多av在线 | 欧美精品一区二区三区潮喷b2 | 午夜中文字幕一区 | 久热中文字幕 | 国产激情婷婷蜜臀 | 欧美日韩在线播放网址 | 乱色老熟妇一区二区三区老牛影视 | 99re在线精品| 亚洲女子高潮不断爆白浆 | 午夜一级成年大片在线 | 萌白酱在线喷水观看尤物视频 | 国产人产一区二 | 日本女优一区二区三区四区 | 99久久国产精品第一页 | 国产 日韩 一线 二线 在线 | 免费污视频在线观看 | 欧美野人三级经典在线观看 | 久久久精品人妻一区二区三区蜜桃 | 四虎成人精品国产永久免费无 | 国产欧美一区二 | 人人碰国产免费线观看 | 欧美日韩精品一区二区三区蜜桃 | 狼友视频在线观看第二 | 91香蕉视频官网 | 欧美日韩中文在线视频 | 午夜男女爽爽爽免费播放 | AA视频黄色| 美女视频黄都免费 | 国产爆乳成 | 日本少妇久久看高潮喷 | 欧美一级视频在线观看 | 国产一级特黄a大片 | 日韩一区二区久久久久久久久 | 日本理伦片午夜理伦片 | 91人人妻人人爽人人搡 | 免费一级做a爰片久久毛片潮 | 国产91中文在线播放 | 无套中出极品少妇 | 91精品网站 | 国产日韩在线观看香 |